Literature DB >> 15016854

Isolation of human monoclonal antibodies that neutralize human rotavirus.

Kyoko Higo-Moriguchi1, Yasushi Akahori, Yoshitaka Iba, Yoshikazu Kurosawa, Koki Taniguchi.   

Abstract

A human antibody library constructed by utilizing a phage display system was used for the isolation of human antibodies with neutralizing activity specific for human rotavirus. In the library, the Fab form of an antibody fused to truncated cp3 is expressed on the phage surface. Purified virions of strain KU (G1 serotype and P[8] genotype) were used as antigen. Twelve different clones were isolated. Based on their amino acid sequences, they were classified into three groups. Three representative clones-1-2H, 2-3E, and 2-11G-were characterized. Enzyme-linked immunosorbent assay with virus-like particles (VLP-VP2/6 and VLP-VP2/6/7) and recombinant VP4 protein produced from baculovirus recombinants indicated that 1-2H and 2-3E bind to VP4 and that 2-11G binds to VP7. The neutralization epitope recognized by each of the three human antibodies might be human specific, since all of the antigenic mutants resistant to mouse monoclonal neutralizing antibodies previously prepared were neutralized by the human antibodies obtained here. After conversion from the Fab form of an antibody into immunoglobulin G1, the neutralizing activities of these three clones toward various human rotavirus strains were examined. The 1-2H antibody exhibited neutralizing activity toward human rotaviruses with either the P[4] or P[8] genotype. Similarly, the 2-3E antibody showed cross-reactivity against HRVs with the P[6], as well as the P[8] genotype. In contrast, the 2-11G antibody neutralized only human rotaviruses with the G1 serotype. The concentration of antibodies required for 50% neutralization ranged from 0.8 to 20 micro g/ml.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15016854      PMCID: PMC371047          DOI: 10.1128/jvi.78.7.3325-3332.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  Passive protection against rotavirus-induced diarrhea by monoclonal antibodies to surface proteins vp3 and vp7.

Authors:  P A Offit; R D Shaw; H B Greenberg
Journal:  J Virol       Date:  1986-05       Impact factor: 5.103

2.  Infection immunity of piglets to either VP3 or VP7 outer capsid protein confers resistance to challenge with a virulent rotavirus bearing the corresponding antigen.

Authors:  Y Hoshino; L J Saif; M M Sereno; R M Chanock; A Z Kapikian
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

3.  Preparation and characterization of neutralizing monoclonal antibodies with different reactivity patterns to human rotaviruses.

Authors:  K Taniguchi; S Urasawa; T Urasawa
Journal:  J Gen Virol       Date:  1985-05       Impact factor: 3.891

4.  Single gene substitution rotavirus reassortants containing the major neutralization protein (VP7) of human rotavirus serotype 4.

Authors:  K Midthun; Y Hoshino; A Z Kapikian; R M Chanock
Journal:  J Clin Microbiol       Date:  1986-11       Impact factor: 5.948

5.  Analysis of serotype-specific neutralization epitopes on VP7 of human rotavirus by the use of neutralizing monoclonal antibodies and antigenic variants.

Authors:  Y Morita; K Taniguchi; T Urasawa; S Urasawa
Journal:  J Gen Virol       Date:  1988-02       Impact factor: 3.891

6.  Relative concentrations of serum neutralizing antibody to VP3 and VP7 proteins in adults infected with a human rotavirus.

Authors:  R L Ward; D R Knowlton; G M Schiff; Y Hoshino; H B Greenberg
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

7.  Independent segregation of two antigenic specificities (VP3 and VP7) involved in neutralization of rotavirus infectivity.

Authors:  Y Hoshino; M M Sereno; K Midthun; J Flores; A Z Kapikian; R M Chanock
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

8.  Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro.

Authors:  C F Barbas; E Björling; F Chiodi; N Dunlop; D Cababa; T M Jones; S L Zebedee; M A Persson; P L Nara; E Norrby
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

9.  Development of an artificial antibody system with multiple valency using an Fv fragment fused to a fragment of protein A.

Authors:  W Ito; Y Kurosawa
Journal:  J Biol Chem       Date:  1993-09-25       Impact factor: 5.157

10.  Cross-reactive neutralization epitopes on VP3 of human rotavirus: analysis with monoclonal antibodies and antigenic variants.

Authors:  K Taniguchi; Y Morita; T Urasawa; S Urasawa
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

View more
  10 in total

1.  Isolation of a human monoclonal antibody with strong neutralizing activity against diphtheria toxin.

Authors:  Mai Kakita; Tsuyoshi Takahashi; Takako Komiya; Yoshitaka Iba; Takao Tsuji; Yoshikazu Kurosawa; Motohide Takahashi
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

2.  High-resolution molecular and antigen structure of the VP8* core of a sialic acid-independent human rotavirus strain.

Authors:  Nilah Monnier; Kyoko Higo-Moriguchi; Zhen-Yu J Sun; B V Venkataram Prasad; Koki Taniguchi; Philip R Dormitzer
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

3.  Multiple Introductions and Antigenic Mismatch with Vaccines May Contribute to Increased Predominance of G12P[8] Rotaviruses in the United States.

Authors:  Kristen M Ogden; Yi Tan; Asmik Akopov; Laura S Stewart; Rendie McHenry; Christopher J Fonnesbeck; Bhinnata Piya; Maximilian H Carter; Nadia B Fedorova; Rebecca A Halpin; Meghan H Shilts; Kathryn M Edwards; Daniel C Payne; Mathew D Esona; Slavica Mijatovic-Rustempasic; James D Chappell; John T Patton; Natasha B Halasa; Suman R Das
Journal:  J Virol       Date:  2018-12-10       Impact factor: 5.103

4.  Human VP8* mAbs neutralize rotavirus selectively in human intestinal epithelial cells.

Authors:  Ningguo Feng; Liya Hu; Siyuan Ding; Mrinmoy Sanyal; Boyang Zhao; Banumathi Sankaran; Sasirekha Ramani; Monica McNeal; Linda L Yasukawa; Yanhua Song; B V Venkataram Prasad; Harry B Greenberg
Journal:  J Clin Invest       Date:  2019-08-12       Impact factor: 14.808

5.  Conserved neutralizing epitope at globular head of hemagglutinin in H3N2 influenza viruses.

Authors:  Yoshitaka Iba; Yoshifumi Fujii; Nobuko Ohshima; Tomomi Sumida; Ritsuko Kubota-Koketsu; Mariko Ikeda; Motoaki Wakiyama; Mikako Shirouzu; Jun Okada; Yoshinobu Okuno; Yoshikazu Kurosawa; Shigeyuki Yokoyama
Journal:  J Virol       Date:  2014-04-09       Impact factor: 5.103

6.  Characterization of neutralizing epitopes of varicella-zoster virus glycoprotein H.

Authors:  Yasushi Akahori; Kazuhiro Suzuki; Tohru Daikoku; Masae Iwai; Yoshihiro Yoshida; Yoshizo Asano; Yoshikazu Kurosawa; Kimiyasu Shiraki
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

7.  Three Types of Broadly Reacting Antibodies against Influenza B Viruses Induced by Vaccination with Seasonal Influenza Viruses.

Authors:  Daisuke Hirano; Nobuko Ohshima; Ritsuko Kubota-Koketsu; Ayami Yamasaki; Gene Kurosawa; Yoshinobu Okuno; Shunji Yoshida; Yoshikazu Kurosawa
Journal:  J Immunol Res       Date:  2018-05-08       Impact factor: 4.818

Review 8.  The growth and potential of human antiviral monoclonal antibody therapeutics.

Authors:  Wayne A Marasco; Jianhua Sui
Journal:  Nat Biotechnol       Date:  2007-12       Impact factor: 54.908

9.  Development of an Automated Chemiluminescent Enzyme Immunoassay for Measuring Thrombopoietin in Human Plasma.

Authors:  Yukihiro Nishikawa; Shiyo Nishida; Keiko Kuroda; Hirokazu Kashiwagi; Yoshiaki Tomiyama; Masataka Kuwana
Journal:  Diagnostics (Basel)       Date:  2022-01-26

Review 10.  Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1.

Authors:  Zhongyu Zhu; Ponraj Prabakaran; Weizao Chen; Christopher C Broder; Rui Gong; Dimiter S Dimitrov
Journal:  Virol Sin       Date:  2013-04-11       Impact factor: 4.327

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.